# MONA Goes LISA

# Changing the Fine Art of STEMI Management

#### Jeffrey M. Goodloe, MD, NRP, FACEP, FAEMS

Medical Director, Medical Control Board EMS System for Metropolitan Oklahoma City & Tulsa Professor & EMS Section Chief, Department of Emergency Medicine University of Oklahoma School of Community Medicine Medical Director, Oklahoma Highway Patrol



# What's the problem with MONA?











## Morphine









## Oxygen

#### The NEW ENGLAND JOURNAL of MEDICINE

#### ORIGINAL ARTICLE

### Oxygen Therapy in Suspected Acute Myocardial Infarction

Robin Hofmann, M.D., Stefan K. James, M.D., Ph.D., Tomas Jernberg, M.D., Ph.D., Bertil Lindahl, M.D., Ph.D., David Erlinge, M.D., Ph.D., Nils Witt, M.D., Ph.D., Gabriel Arefalk, M.D., Mats Frick, M.D., Ph.D., Joakim Alfredsson, M.D., Ph.D., Lennart Nilsson, M.D., Ph.D., Annica Ravn-Fischer, M.D., Ph.D., Elmir Omerovic, M.D., Ph.D., Thomas Kellerth, M.D., David Sparv, B.Sc., Ulf Ekelund, M.D., Ph.D., Rickard Linder, M.D., Ph.D., Mattias Ekström, M.D., Ph.D., Jörg Lauermann, M.D., Urban Haaga, B.Sc., John Pernow, M.D., Ph.D., Ollie Östlund, Ph.D., Johan Herlitz, M.D., Ph.D., and Leif Svensson, M.D., Ph.D., for the DETO2X–SWEDEHEART Investigators\*



#### Hofmann R, et al. NEJM 377;13 (Sept 28, 2017)



## Oxygen

#### The NEW ENGLAND JOURNAL of MEDICINE

#### ORIGINAL ARTICLE

CONCLUSIONS Routine use of supplemental oxygen in patients with suspected myocardial infarction who did not have hypoxemia was not found to reduce 1-year all-cause mortality.

> Elmir Omerovic, M.D., Ph.D., Thomas Kellerth, M.D., David Sparv, B.Sc., Ulf Ekelund, M.D., Ph.D., Rickard Linder, M.D., Ph.D., Mattias Ekström, M.D., Ph.D., Jörg Lauermann, M.D., Urban Haaga, B.Sc., John Pernow, M.D., Ph.D., Ollie Östlund, Ph.D., Johan Herlitz, M.D., Ph.D., and Leif Svensson, M.D., Ph.D., for the DETO2X–SWEDEHEART Investigators\*





Hofmann R, et al. NEJM 377;13 (Sept 28, 2017)

## Oxygen

#### Effect of supplemental oxygen exposure on myocardial injury in STelevation myocardial infarction

Ziad Nehme<sup>1, 2</sup>, Dion Stub<sup>2, 3, 4, 5</sup>, Stephen Bernard<sup>1, 2, 3</sup>, Michael Stephenson<sup>1</sup>, Janet E Bray<sup>2, 3</sup>, Peter Cameron<sup>2, 3</sup>, Ian T Meredith<sup>6</sup>, Bill Barger<sup>1</sup>, Andris H Ellims<sup>3, 4</sup>, Andrew J Taylor<sup>3, 4</sup>, David M Kaye<sup>2, 3, 4</sup>, Karen Smith<sup>1, 2, 7</sup> for the AVOID Investigators Author affiliations +

#### Abstract

**Objective** Supplemental oxygen therapy may increase myocardial injury following ST-elevation myocardial infarction (STEMI). In this study, we aimed to evaluate the effect of the dose and duration of oxygen exposure on myocardial injury after STEMI.





Nehme Z et al. Heart. 2016 Mar;102(6):444-51

# Results of the AVOID Trial

- Every 100 L increase in oxygen exposure in the first 12 h was associated with a 1.4% (95% CI 0.6% to 2.2%, p<0.001) and 1.2% (95% CI 0.7% to 1.8%, p<0.001) increase in the mean peak cTnl and CK, respectively.
- The median supplemental oxygen exposure of 1746 L would result in a <u>21%</u> (95% CI 3% to 37%) <u>increase in infarct size</u> according to the cTnI profile.





# Results of the AVOID Trial

 Every 100 L increase in oxygen exposure in the first 12 h was associated with a 1.4% (95% CI 0.6% to 2.2%, p<0.001) and 1.2% (95% CI 0.7% CONCLUSIONS Supplemental oxygen exposure in the first 12 h after STEMI was associated with a clinically significant increase in cTnI and CK release. 1746 L would result in a 21% (95% CI 3% to 37%) increase in infarct size according to the cTnl profile.



Nehme Z et al. Heart. 2016 Mar;102(6):444-51

# A word about nitroglycerin







## A word about nitroglycerin





## Aspirin

## CARDIOLOGY

Coronary Care

#### Outcome of Myocardial Infarction in Patients Treated with Aspirin Is Enhanced by Pre-Hospital Administration

Barbash I.M.<sup>a</sup> · Freimark D.<sup>a</sup> · Gottlieb S.<sup>a</sup> · Hod H.<sup>a</sup> · Hasin Y.<sup>a</sup> · Battler A.<sup>b</sup> · Crystal E.<sup>a</sup> · Matetzky S.<sup>a</sup> · Boyko V.<sup>a</sup> · Mandelzweig L.<sup>a</sup> · Behar S.<sup>a</sup> · Leor J.<sup>a</sup>



Barbash IM et al. Cardiology 2002; 98(3):141-7



# **Pre-Hospital Aspirin**

- Independent determinant of survival
- 7 day survival (OR 0.43; 95% CI 0.18–0.92)
- 30 day survival (OR 0.60; 95% CI 0.32–1.08).
- Benefit even if NOT treated with reperfusion

Aspirin in acute STEMI saves lives. Give it.







# LISA

L let ED/cardiology/cath know early -> 12-lead ECG telemetry/cath activation interventional destination (cath lab) S scene coordination to save time -> defined roles (ala cardiac arrest style) aspirin



